ArticleNeurocritical care2009
Conivaptan for hyponatremia in the neurocritical care unit.
Article in Neurocritical care, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03000283 (Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability Study), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability Study
Who cites it
17 citing papers in PubMed, 66 citations in OpenAlex.
- Open-label randomized trial of the safety and efficacy of a single dose conivaptan to raise serum sodium in patients with traumatic brain injury.Neurocritical care · 2011Trial
- Use of Conivaptan (Vaprisol) for hyponatremic neuro-ICU patients.Neurocritical care · 2010Trial
- Repurposing FDA approved drugs against monkeypox virus DNA dependent RNA polymerase: virtual screening, normal mode analysis and molecular dynamics simulation studies.Virusdisease · 2024Article
- Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage: A Safety and Tolerability Study.Clinical drug investigation · 2020Article
- Mechanism, spectrum, consequences and management of hyponatremia in tuberculous meningitis.Wellcome open research · 2019Review
- Efficacy of conivaptan and hypertonic (3%) saline in treating hyponatremia due to syndrome of inappropriate antidiuretic hormone in a tertiary Intensive Care Unit.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2016Article
- Diagnosis and Management of Hyponatremia in Patients with Aneurysmal Subarachnoid Hemorrhage.Journal of clinical medicine · 2015Article
- Treatment of endocrine disorders in the neuroscience intensive care unit.Current treatment options in neurology · 2014Article
- Sodium and fluid management in acute brain injury.Current neurology and neuroscience reports · 2012Review
- Urea for treatment of acute SIADH in patients with subarachnoid hemorrhage: a single-center experience.Annals of intensive care · 2012Article
- Syndrome of inappropriate antidiuresis and cerebral salt wasting syndrome: are they different and does it matter?Pediatric nephrology (Berlin, Germany) · 2012Article
- Intensive care unit management of aneurysmal subarachnoid hemorrhage.Current neurology and neuroscience reports · 2012Article
- Novel treatment targets for cerebral edema.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2012Review
- A bolus of conivaptan lowers intracranial pressure in a patient with hyponatremia after traumatic brain injury.Neurocritical care · 2011Article
- Conivaptan and its role in the treatment of hyponatremia.Drug design, development and therapy · 2009Article
- Non-peptide arginine-vasopressin antagonists (vaptans) for the treatment of hyponatremia in neurocritical care: a new alternative?Neurocritical care · 2009Article
- Efficacy of 3% saline vs. conivaptan in achieving hyponatremia treatment goals.Methodist DeBakey cardiovascular journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionConivaptan is the first arginine vasopressin antagonist to be FDA-approved for the treatment of euvolemic hyponatremia, a common complication in neurointensive care patients. Due to risks for cerebral edema and seizures, sodium levels are generally aggressively maintained within normal levels (135-145 meq/l) in this patient population.
objectiveTo assess the safety and efficacy of conivaptan for the treatment of euvolemic hyponatremia in the neurocritical care unit.
methodsData were obtained retrospectively on 22 patients treated with conivaptan for euvolemic hyponatremia. End points evaluated included time to [Na] increase of >or=6 meq/l; incidences of rapid overcorrection of [Na] (defined as an increase of >12 meq/l in a 24-h period while on conivaptan), infusion site reactions, or other adverse events; and whether sodium levels decreased after discontinuation of conivaptan.
resultsA [Na] increase of >or=6 meq/l was reached in 19/22 (86%) patients, with an average time to goal of 13.1 h. No patients experienced a rapid overcorrection of [Na]. Five patients had an infusion site reaction necessitating an IV change. One patient experienced hypotension and another complained of thirst during infusion. Conivaptan was initiated in 11/22 patients (50%) who were hyponatremic despite already being on conventional therapies.
conclusionConivaptan was safe and effective in this small series of neurointensive care patients, including many patients who were hyponatremic despite traditional treatments to maintain normal sodium levels. Further studies are needed to clarify the role of conivaptan as an adjunctive and/or alternative therapy for hyponatremia in this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.